Investigational Drug Information for Basimglurant
What is the development status for investigational drug Basimglurant?
Basimglurant is an investigational drug.
There have been 3 clinical trials for Basimglurant.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 11th 2022.
The most common disease conditions in clinical trials are Depressive Disorder, Trigeminal Neuralgia, and Depression. The leading clinical trial sponsors are Noema Pharma AG, Hoffmann-La Roche, and [disabled in preview].
Summary for Basimglurant
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 84 |
| WIPO Patent Applications | 24 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 1 (2022-01-11) |
| Vendors | 0 |
Recent Clinical Trials for Basimglurant
| Title | Sponsor | Phase |
|---|---|---|
| An Efficacy and Safety Study of Basimglurant in Patients With Trigeminal Neuralgia. | Noema Pharma AG | Phase 2/Phase 3 |
| Basimglurant in Children and Adolescents With TSC | Noema Pharma AG | Phase 2 |
| A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD) | Hoffmann-La Roche | Phase 1 |
Clinical Trial Summary for Basimglurant
Top disease conditions for Basimglurant
Top clinical trial sponsors for Basimglurant
US Patents for Basimglurant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Basimglurant Development Update and Market Projection
Basimglurant is an oral, selective negative allosteric modulator of the metabotropic glutamate 5 receptor, or mGluR5. Roche developed the compound under the codes RO4917523 and RG7090 for major depressive disorder, treatment-resistant depression, fragile X syndrome and other central nervous system indications.
The program has no FDA approval, no marketed formulation, no Orange Book listing and no active registrational development program publicly identified through 2024. Roche’s clinical development produced mixed or negative efficacy results, and basimglurant is best classified as a discontinued or dormant asset rather than an emerging commercial launch candidate. Current direct product revenue is zero. Any value depends on a new license, a new clinical strategy or evidence supporting a different indication.
What is the current development status of basimglurant?
Basimglurant has completed mid-stage clinical testing but has not advanced to an FDA registration filing.
| Development attribute | Status |
|---|---|
| Active ingredient | Basimglurant |
| Development codes | RO4917523, RG7090 |
| Mechanism | Selective mGluR5 negative allosteric modulator |
| Primary developer | Roche |
| Dosage form studied | Oral tablets |
| Lead indications | Major depressive disorder, treatment-resistant depression, fragile X syndrome |
| FDA approval | None |
| Biologics license application | Not applicable |
| New drug application | No publicly disclosed filing |
| Orange Book listing | None |
| Commercial sales | None |
| Current registrational trial | No publicly identified active program |
| Biosimilar exposure | None; basimglurant is a small molecule |
| Generic exposure | Relevant only if the compound is relaunched and approved |
Roche evaluated basimglurant in randomized clinical studies involving depression and fragile X syndrome. The compound was part of a broader effort to develop glutamatergic therapies that could act without the dissociative and abuse-related liabilities associated with some other central nervous system mechanisms.
Public trial records and published clinical reports do not show progression to Phase 3 development or regulatory submission. The absence of a current pivotal program is the main commercial fact affecting the asset’s value. (ClinicalTrials.gov, n.d.; Roche, 2016)
What clinical results affected basimglurant development?
Major depressive disorder and treatment-resistant depression
Basimglurant was tested as an adjunctive treatment in patients who had an incomplete response to antidepressants. The clinical rationale was that mGluR5 modulation could influence glutamate signaling, synaptic plasticity and mood-related neural circuits.
The depression program did not generate a sufficiently consistent efficacy profile to support a late-stage registration strategy. Clinical outcomes were affected by several factors:
- Modest or inconsistent separation from placebo.
- Heterogeneous treatment-resistant depression populations.
- High placebo response, which is common in antidepressant trials.
- Unclear identification of patients most likely to respond to mGluR5 inhibition.
- Limited evidence that the benefit-risk profile was superior to established augmentation treatments.
The failure of several glutamatergic programs during the same period reduced the commercial attractiveness of an undifferentiated oral depression therapy. Basimglurant did not establish a clinically validated biomarker-defined population.
Fragile X syndrome
Fragile X syndrome provided a mechanistically attractive indication because excessive mGluR5 signaling had been implicated in disease biology. Basimglurant was evaluated in adults with fragile X syndrome, but the program did not produce a sufficiently robust clinical benefit across the principal measures used to support continuation.
The fragile X opportunity remains commercially significant in principle because it is a rare neurodevelopmental disorder with limited approved pharmacologic options. The indication is difficult to commercialize, however, because clinical endpoints are complex, patient populations are small and prior mGluR5 studies generated mixed results.
A successful relaunch would require new evidence that basimglurant improves a clinically meaningful outcome, not only a mechanistic or behavioral measure.
What is the FDA regulatory status of basimglurant?
Basimglurant has no FDA approval and no public FDA label. It is not listed in the FDA Orange Book as an approved drug product.
Because there is no approved product:
- No five-year new chemical entity exclusivity has been granted.
- No three-year clinical investigation exclusivity has been granted.
- No orphan-drug exclusivity has been awarded for basimglurant.
- No pediatric exclusivity is publicly associated with the compound.
- No Paragraph IV certification can currently be filed against an approved basimglurant product.
- No abbreviated new drug application can currently be approved against a basimglurant reference product.
If Roche or a new sponsor revives the program, the regulatory pathway would probably require a new IND strategy and new pivotal evidence. Prior Phase 2 results would support development planning but would not substitute for current efficacy and safety data.
What patents protect basimglurant?
The historical patent estate is expected to include composition-of-matter, pharmaceutical-composition, therapeutic-use and manufacturing-related claims. Public regulatory records do not identify an active Orange Book patent estate because basimglurant has never been approved.
| Patent category | Commercial relevance |
|---|---|
| Composition of matter | Historically the most important protection for the active molecule |
| Salt, polymorph or solid-state claims | Could protect particular drug substances or manufacturing forms |
| Pharmaceutical composition | Could cover tablets, excipients and dosage ranges |
| Method of use | Could cover depression, fragile X syndrome or other neurological disorders |
| Manufacturing process | Could create technical barriers if the synthesis is difficult |
| Formulation | Potentially relevant for controlled release, stability or bioavailability |
| Orange Book patent | None publicly listed because no approved product exists |
The likely age of the original composition-of-matter filings creates a major lifecycle problem. Basimglurant entered clinical development in the late 2000s, so basic composition claims would generally be approaching or past their ordinary 20-year term from the earliest nonprovisional priority date, subject to jurisdiction-specific adjustments, terminal disclaimers and patent-term restoration.
Later method-of-use or formulation patents could extend protection if they were granted and remain enforceable. They would not restore broad exclusivity over the molecule unless their claims covered commercially necessary uses or formulations. A new sponsor would need a verified patent-family review covering the United States, Europe, Japan and other target markets before assigning material value to the asset.
When does basimglurant lose exclusivity?
Basimglurant has no approved-product exclusivity timeline. Patent expiry is more relevant than regulatory exclusivity, but a single definitive loss-of-exclusivity date cannot be assigned to the compound without identifying the relevant granted patent family and calculating applicable term adjustments.
The commercial implications are clear:
- Any original composition patent is likely to be late-life or expired in major jurisdictions.
- Later use patents may remain relevant for a specific indication.
- A relaunch would require new intellectual-property protection around formulation, dosing, patient selection or a newly validated use.
- Regulatory exclusivity would arise only after a new approval and would depend on the eventual FDA designation and indication.
A new sponsor would therefore be unlikely to obtain strong, broad protection simply by licensing the historical asset. The strongest potential protection would come from a new clinical profile supported by a patentable dosing regimen, biomarker-selected population or differentiated formulation.
Are there Paragraph IV challenges or basimglurant patent lawsuits?
No publicly identified Paragraph IV litigation affects basimglurant because there is no approved reference product and no Orange Book listing.
No major U.S. patent litigation involving an ANDA challenger has been publicly associated with basimglurant. Any historical patent disputes would be more likely to involve prosecution, opposition or ownership issues than generic-entry litigation.
The absence of litigation is not evidence of a strong patent position. It mainly reflects the absence of a commercial product and generic filing opportunity.
Are there licensing deals for basimglurant?
Roche is the principal publicly associated developer. No active licensing transaction transferring basimglurant to a commercial-stage sponsor has been broadly disclosed in the public domain through 2024.
A transaction would likely be structured as an option, regional license or low-upfront asset sale rather than a large strategic acquisition. The economic rationale for a buyer would depend on:
- Access to the original clinical and pharmacology package.
- Freedom to operate around composition and use patents.
- A credible new indication.
- Ability to reproduce or improve the formulation.
- A biomarker strategy that can reduce clinical heterogeneity.
- A regulatory pathway that avoids repeating failed development assumptions.
The absence of a disclosed partner limits evidence of external validation. It also suggests that the asset has not yet met the diligence threshold required for a meaningful commercial collaboration.
How strong is the basimglurant patent estate?
The patent estate is strategically weak for broad commercial protection but potentially useful for a targeted redevelopment program.
| Patent-strength factor | Assessment |
|---|---|
| Broad molecule protection | Likely late-life or expired, depending on jurisdiction |
| Approved-product exclusivity | None |
| Orange Book leverage | None |
| Method-of-use protection | Potentially relevant if unexpired |
| Formulation protection | Potentially relevant but narrower |
| Manufacturing protection | Could restrict some suppliers without blocking all alternatives |
| Freedom to operate | Requires jurisdiction-specific review |
| Ability to delay generic entry | Low without a new approval and surviving use claims |
| Value of historical data package | Moderate for hypothesis generation, limited for registration |
A compound with no approval and no active Phase 3 program is generally valued on redevelopment probability rather than patent duration. Basimglurant’s intellectual-property position could support a niche transaction if new data show efficacy in a defined population. It is unlikely to support a conventional high-value branded launch based solely on the original development record.
What is the market projection for basimglurant?
The base-case market projection is zero commercial revenue through 2030 because no sponsor has publicly advanced the compound into a registrational program.
An upside case exists if a new developer demonstrates efficacy in a narrow indication such as treatment-resistant depression or fragile X syndrome. The table below presents an unadjusted peak-sales framework, not a reported company forecast.
| Scenario | Development assumption | Potential peak annual sales | Probability-adjusted commercial view |
|---|---|---|---|
| Base case | No restart; asset remains dormant | $0 | Dominant scenario |
| Low upside | Single niche indication with modest efficacy | $50 million-$150 million | Limited |
| Moderate upside | Approval in treatment-resistant depression with differentiated use | $200 million-$500 million | Low probability |
| High upside | Broad psychiatric adoption plus rare-disease positioning | $500 million-$1 billion | Very low probability |
Treatment-resistant depression is the larger theoretical market, but competition is intense. Approved and established alternatives include atypical antipsychotic augmentation, esketamine, intranasal therapies and multiple generic antidepressants. A new basimglurant product would need a clear advantage in tolerability, speed of onset, abuse potential, metabolic effects or patient selection.
Fragile X syndrome offers a smaller patient population but potentially stronger pricing and orphan-drug economics. It also presents greater clinical risk because prior mGluR5-based approaches have not produced a reliable class-wide proof of concept.
A practical risk-adjusted valuation would be materially below the unadjusted peak-sales figures. Until a sponsor announces a new IND, a clinical hold-lifted program or a Phase 2 restart, a financial model should assign little or no near-term revenue.
How does basimglurant compare with competing neuropsychiatric drugs?
| Product or class | Regulatory position | Commercial comparison |
|---|---|---|
| Basimglurant | Unapproved, dormant | No current revenue; redevelopment risk is high |
| Esketamine | FDA-approved for defined depression uses | Established commercial and regulatory precedent, with administration and safety burdens |
| Atypical antipsychotic augmentation | Multiple approved products | Generic competition and established prescribing behavior |
| Brexpiprazole | Approved for adjunctive major depressive disorder | Branded and generic lifecycle dynamics differ by market |
| Zuranolone | Approved for postpartum depression | Demonstrates demand for novel rapid-acting neuropsychiatric mechanisms |
| Fragile X investigational therapies | No broadly established pharmacologic standard | Small market with high endpoint and development risk |
Basimglurant could be differentiated from some competitors by oral administration and the absence of a biologic manufacturing burden. That advantage would not overcome weak efficacy or limited patent protection.
What generic launch risks exist for basimglurant?
There is no immediate generic launch risk because no basimglurant reference product is approved. If the compound were relaunched, the principal generic risks would include:
- Limited remaining composition-of-matter protection.
- ANDA filing after approval of a new reference product.
- Narrow method-of-use patents that may be avoidable through labeling.
- Alternative formulations that bypass formulation claims.
- Competition from existing generic antidepressants.
- Price pressure if approval is based on a broad, non-orphan indication.
A new sponsor would need to build a lifecycle strategy before pivotal trials begin. The strategy could include a proprietary formulation, a protected dosing schedule, a biomarker-defined population and indication-specific use claims.
What manufacturing and geographic barriers affect basimglurant?
Basimglurant is a small molecule, so it does not face the cell-line, cold-chain and comparability barriers associated with biologics. Manufacturing barriers could still arise from:
- Multi-step synthesis.
- Chiral control or impurity management.
- Solid-state selection.
- Tablet stability.
- Scale-up yield and cost.
- Supplier qualification for active pharmaceutical ingredient production.
Geographic protection is likely to be uneven. U.S. and European rights would determine the largest commercial opportunity, while Japan, Canada, Australia and emerging markets would affect secondary revenue. Patent expiration and prosecution history may differ by jurisdiction. A global launch would require a country-by-country review of surviving claims and regulatory data requirements.
What is the investment outlook for basimglurant?
Basimglurant is an option-value asset, not a current commercial asset. Its investment profile has four defining characteristics:
- No approved product or current revenue.
- No active late-stage clinical program.
- A historical mechanism with incomplete clinical validation.
- Potentially limited remaining broad patent protection.
The asset could become relevant again if new neuroscience data identify a responsive patient subgroup. Without that evidence, a license would likely be justified only at a low upfront value with milestone-heavy consideration and a clear termination option.
Key Takeaways
- Basimglurant is an unapproved Roche-developed mGluR5 negative allosteric modulator.
- Its principal development areas were depression, treatment-resistant depression and fragile X syndrome.
- The program did not progress to a publicly disclosed Phase 3 registration effort.
- FDA approval, Orange Book listing, regulatory exclusivity and commercial revenue are absent.
- No Paragraph IV litigation or generic challenge is currently relevant.
- Historical composition patents are likely late-life or expired, while any surviving use or formulation claims require a detailed family review.
- The base-case market projection through 2030 is zero revenue.
- A relaunch could support a niche opportunity, but the probability of commercial success is low without new clinical evidence and new patent protection.
FAQs
Is basimglurant the same as an antidepressant?
Basimglurant was investigated as an adjunctive treatment for depression, but it is not an FDA-approved antidepressant and has no approved prescribing indication.
Can basimglurant still be developed for fragile X syndrome?
Yes, in principle. A new sponsor could initiate a new development program, but it would need fresh clinical evidence and a regulatory strategy that addresses prior mixed mGluR5 results.
Does basimglurant have orphan-drug exclusivity?
No publicly identified FDA orphan-drug exclusivity applies to basimglurant because the compound has not received an FDA approval for an orphan indication.
Is basimglurant a biologic or a small-molecule drug?
Basimglurant is a small molecule administered orally. Biosimilar competition is therefore not applicable, although generic competition could arise after any future approval.
Could basimglurant reach the market before 2030?
Only if a new sponsor restarts development, completes new clinical studies and secures regulatory approval. Based on the public development record through 2024, a pre-2030 launch is unlikely.
References
-
ClinicalTrials.gov. (n.d.). Studies involving basimglurant, RO4917523, or RG7090. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
European Medicines Agency. (n.d.). European public assessment reports and medicines database. https://www.ema.europa.eu/
-
Roche. (2016). Annual report 2016. F. Hoffmann-La Roche Ltd.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
World Health Organization. (n.d.). International nonproprietary names for pharmaceutical substances: Basimglurant. https://www.who.int/teams/health-product-policy-and-standards/inn
More… ↓
